An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00918606

Enrollment

Registered

2009-06-11

Start date

2009-02-28

Completion date

2009-06-30

Last updated

2015-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subcutaneous Adipose Tissue Reduction

Brief summary

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Interventions

DRUGLIPO-102

LIPO-102

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Male and non pregnant female * 18-55 years old * Sufficient abdominal fat for injections * Signed informed consent

Exclusion criteria

* Known hypersensitivity to study drugs * Treatment with an investigational agent within 30 days before first dose

Design outcomes

Primary

Measure	Time frame
Safety: Laboratory tests, medical exams	4 weeks

Secondary

Measure	Time frame
Pharmacokinetics	24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026